Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2011

View Archived Issues

New tyrosine-protein kinase SYK inhibitors presented

New HIV-1 clade C consensus envelope sequence-based DNA vaccine is immunogenic in vivo

Novel imidazo[1,2-b]pyridazine derivative ameliorates symptoms of arthritis in vivo

New dipeptidyl peptidase 1 inhibitors claimed

Sanofi discloses novel pim inhibitors for cancer

Katholieke Universiteit Leuven describes new antifungal agents

Photocure begins enrollment in new phase II Visonac study

Merck & Co.'s new frizzled SMO receptor antagonist MK-5710 has antitumor activity in vivo

New MAP kinase-activated protein kinase 2 inhibitors discovered

PET tracer [18F]-MK-3328 shows favorable uptake in brain of patients with AD

Janssen Pharmaceuticals to divest U.S. Ortho Dermatologics division

FDA approves delayed-release mesalamine tablets for maintenance of remission of ulcerative colitis

COMP recommends orphan drug status for Nektar Therapeutics' lead oncology agent in ovarian cancer

Afexa Life Sciences clear to begin study of AFX-2 in patients with chronic lymphocytic leukemia

Cyclacel and Daiichi Sankyo amend sapacitabine licensing agreement

Daiichi Sankyo launches Lixiana in Japan

Nabi Biopharmaceuticals reports on first confirmatory phase III NicVAX study

Talon Therapeutics submits NDA for Marqibo to FDA

Dificid tablets launched in U.S. for CDI-associated diarrhea

Halaven launched in Japan for inoperable/recurrent breast cancer

Merck & Co. gains European approval for Victrelis

Japanese launch of Rivastach patch for Alzheimer's type-dementia

Chugai set to launch Mircera injection syringe in Japan for treatment of renal anemia

Phase III data presented on subcutaneous Actemra versus intravenous infusion

Upsher-Smith Laboratories initiates phase III trial of USL-261

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...